-

12:00:18 AM

AXLA Stock News

AXLA - Axcella Health Inc

05/04/23 4:30 PM

Nasdaq : AXLA

earnings

Axcella Reports First Quarter Financial Results and Provides Business Update

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the first quarter ended March 31, 2023 and provided a business update. “Patients are seeking a Long COVID therapy, as we have seen...

RHEA-AI

neutral

04/17/23 8:00 AM

Nasdaq : AXLA

covid-19

Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023

Axcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced two oral presentations of results from the Phase 2 a clinical trial of AXA1125 in the treatment of Long COVID Fatigue at the European Congress of...

RHEA-AI

neutral

03/30/23 8:00 AM

Nasdaq : AXLA

earnings

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. “The year 2022 was one of significant...

RHEA-AI

neutral

02/15/23 4:10 PM

Nasdaq : AXLA

covid-19

Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Axcella Therapeutics, a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced its Investigational New Drug application to initiate a phase 2 b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been...

RHEA-AI

neutral

02/09/23 4:45 PM

Nasdaq : AXLA

conferences

Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities’ 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023.

RHEA-AI

neutral

01/23/23 4:15 PM

Nasdaq : AXLA

covid-19

Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Axcella will be meeting with the MHRA in the near term to discuss the Innovative Licensing and Access Pathway application. The company further reported submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for a Phase 2 b/3 trial. Recent estimates indicate that 15-20% of Americans with COVID have persisting health...

RHEA-AI

neutral

12/14/22 8:01 PM

Nasdaq : AXLA

Axcella Announces Program Reprioritization and Corporate Restructuring

Axcella Therapeutics, a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. “The strategic process we initiate today prioritizes...

RHEA-AI

positive

11/03/22 9:59 AM

Nasdaq : AXLA

conferences

Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases...

RHEA-AI

neutral

11/01/22 7:00 AM

Nasdaq : AXLA

earnings

Axcella Reports Third Quarter Financial Results and Provides Business Update

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “This has been an extremely exciting period for Axcella,”...

RHEA-AI

neutral

10/27/22 8:30 AM

Nasdaq : AXLA

conferencesearnings

Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it plans to report its third quarter 2022 financial results and other business updates on November 1, 2022. The company will host a conference call at...

RHEA-AI

neutral

1 2 3 4 5 6 Next

AXLA Data

IndustryResearch and Development in Biotechnology
Websitewww.axcellahealth.com
Security nameAxcella Health Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2836
Employees59
Tags
- Pharmaceuticals: Major
- Biotechnology
- Health Technology

About Axcella Health Inc

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company's product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella's pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.